Augmenting Anticancer Immunity Through Combined Targeting of Angiogenic and PD-1/PD-L1 Pathways: Challenges and Opportunities.

Front Immunol · 2020 · PMC7674951 · PMID 33250900

Europe PMC DOI

hedged sentence

0.0750

closest p · 1.5× alpha

0.0750

boldest claim

The sentences

did not achieve significanceP = 0.075so close (0.05 < p ≤ 0.1)

sorafenib as a first-line treatment in patients with unresectable HCC, did not achieve significance for its primary endpoint of OS (HR, 0.85; P = 0.075).

also in 1,397 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.